The 3rd annual meeting in Atlanta gives dermatology NPs and PAs 4 case-based breakout sessions and a general education session in a focused, small-group setting.
News|Articles|June 26, 2025
Inside SDPA Summer 2025: Dermatology Times Board Member Presenters
Author(s)Emma Andrus, Editor
Listen
0:00 / 0:00
Key Takeaways
- The 2025 SDPA Annual Summer Dermatology Conference will showcase cutting-edge therapies and real-world strategies in dermatology.
- Dermatology Times editors will offer comprehensive coverage, including session reports, expert interviews, and conference highlights.
Join Dermatology Times at SDPA 2025 as our expert board members take the stage to share clinical insights, pearls, and practice-changing perspectives.
Advertisement
Dermatology Times editors will be onsite at the 2025 Society of Dermatology Physician Associates (SDPA) Annual Summer Dermatology Conference bringing you the latest insights, clinical data, and expert perspectives as they unfold. From cutting-edge therapies to real-world strategies, our team will deliver in-depth session coverage, expert interviews, and can't-miss conference highlights.
Advertisement
Related to this article
SPD 2026 highlighted advances in pediatric dermatology spanning textured hair care, vitiligo, vascular anomalies, mental health, genetics, and collaborative care.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
A retrospective claims analysis of 2897 matched pairs found hazard ratios of 0.48 to 0.67 for new atopic disease with dupilumab vs systemic corticosteroids in children.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Falk G. Bechara, MD, discusses long-term tunnel control, structural damage, and the evolving role of biologics and surgery in HS care.
In a survey of 301 employed adults, overall work impairment attributable to CHE was 31.8%, and quality of life worsened in step with self-reported disease severity.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
Advertisement
Advertisement